- United States
- /
- Chemicals
- /
- NasdaqCM:ORGN
Origin Materials Second Quarter 2024 Earnings: Misses Expectations
Origin Materials (NASDAQ:ORGN) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$7.03m (up 2.0% from 2Q 2023).
- Net loss: US$19.5m (loss widened by 202% from 2Q 2023).
- US$0.14 loss per share (further deteriorated from US$0.046 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Origin Materials Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 9.6%. Earnings per share (EPS) also missed analyst estimates by 17%.
Looking ahead, revenue is forecast to grow 74% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Chemicals industry in the US.
Performance of the American Chemicals industry.
The company's shares are up 74% from a week ago.
Risk Analysis
Be aware that Origin Materials is showing 3 warning signs in our investment analysis and 2 of those shouldn't be ignored...
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

Any moat with an opt-out clause for your competitors is just a fence around your own garden.
Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.
Andrew LeggetGreat earnings season, but are the earnings real?

About NasdaqCM:ORGN
Origin Materials
Engages in the polyethylene terephthalate (PET) closures business in California.
Adequate balance sheet with slight risk.